DE69622472D1 - Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor - Google Patents

Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor

Info

Publication number
DE69622472D1
DE69622472D1 DE69622472T DE69622472T DE69622472D1 DE 69622472 D1 DE69622472 D1 DE 69622472D1 DE 69622472 T DE69622472 T DE 69622472T DE 69622472 T DE69622472 T DE 69622472T DE 69622472 D1 DE69622472 D1 DE 69622472D1
Authority
DE
Germany
Prior art keywords
bef
diseases
induction
treatment
transcription factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69622472T
Other languages
English (en)
Other versions
DE69622472T2 (de
Inventor
David Thompson Berg
David Scott Calnek
Brian William Grinnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69622472D1 publication Critical patent/DE69622472D1/de
Application granted granted Critical
Publication of DE69622472T2 publication Critical patent/DE69622472T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69622472T 1995-06-07 1996-05-30 Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor Expired - Fee Related DE69622472T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47949895A 1995-06-07 1995-06-07

Publications (2)

Publication Number Publication Date
DE69622472D1 true DE69622472D1 (de) 2002-08-29
DE69622472T2 DE69622472T2 (de) 2003-02-06

Family

ID=23904277

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69622472T Expired - Fee Related DE69622472T2 (de) 1995-06-07 1996-05-30 Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor

Country Status (8)

Country Link
EP (1) EP0747051B1 (de)
JP (1) JPH11506771A (de)
AU (1) AU6040296A (de)
BR (1) BR9609053A (de)
CA (1) CA2223175A1 (de)
DE (1) DE69622472T2 (de)
ES (1) ES2180702T3 (de)
WO (1) WO1996040130A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CA2676984C (en) 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (de) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Neuartige heterocyclische verbindungen als bromdomänenhemmer
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
ES2215270T3 (es) * 1993-12-21 2004-10-01 Eli Lilly And Company Inhibicion de productos terminales de glicosilacion avanzada.
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin

Also Published As

Publication number Publication date
EP0747051A3 (de) 1997-02-26
BR9609053A (pt) 1999-01-26
JPH11506771A (ja) 1999-06-15
WO1996040130A1 (en) 1996-12-19
EP0747051A2 (de) 1996-12-11
AU6040296A (en) 1996-12-30
ES2180702T3 (es) 2003-02-16
EP0747051B1 (de) 2002-07-24
CA2223175A1 (en) 1996-12-19
DE69622472T2 (de) 2003-02-06

Similar Documents

Publication Publication Date Title
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
ATE259812T1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
DE69215345D1 (de) Behandlung von Synthesegas
FI972681A (fi) Kynsien sientenvastainen käsittely
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
NO965377L (no) Indolinonforbindelser for behandling av sykdommer
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DK0841946T4 (da) Metoder til behandling af allergisk astma
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DE69622472D1 (de) Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE69841550D1 (de) Behandlung von fibromyalgie und verwandten erkrankungen
DE69619051D1 (de) Behandlung von Füllstoffen mit Oxasilacycloalkanen
DE69518438D1 (de) Behandlung von übereregten nervenzellenfunktionen
EE03437B1 (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
DE69216089D1 (de) Behandlung von aluminiumblechen
DE69212119D1 (de) Behandlung von Fotoresistabfall
DE69816520D1 (de) Behandlung von durch Einzeller verursachte Infektionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee